BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Olías-Molero AI, de la Fuente C, Cuquerella M, Torrado JJ, Alunda JM. Antileishmanial Drug Discovery and Development: Time to Reset the Model? Microorganisms 2021;9:2500. [PMID: 34946102 DOI: 10.3390/microorganisms9122500] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Goel N, Gupta VK, Garg A, Bhoumik A, Biswas R, Natarajan R, Majumder HK, Jaisankar P. Holanamine, a Steroidal Alkaloid from the Bark of Holarrhena pubescens Wall. ex G. Don Inhibits the Growth of Leishmania donovani by Targeting DNA Topoisomerase 1B. ACS Infect Dis 2022. [DOI: 10.1021/acsinfecdis.2c00562] [Reference Citation Analysis]
2 Cunha Araújo IA, Cristina de Paula R, Alves CL, Faria KF, Miguel de Oliveira M, Mendes GG, Ferreira Abdias Dias EM, Braga de Oliveira A, Magno da Silva S. In vitro efficacy of isoflavonoids and terpenes against Leishmania (Leishmania) infantum and L. amazonensis. Exp Parasitol 2022;:108383. [PMID: 36152879 DOI: 10.1016/j.exppara.2022.108383] [Reference Citation Analysis]
3 Abdelkrim YZ, Harigua-Souiai E, Bassoumi-Jamoussi I, Barhoumi M, Banroques J, Essafi-Benkhadir K, Nilges M, Blondel A, Tanner NK, Guizani I. Enzymatic and Molecular Characterization of Anti-Leishmania Molecules That Differently Target Leishmania and Mammalian eIF4A Proteins, LieIF4A and eIF4AMus. Molecules 2022;27:5890. [PMID: 36144626 DOI: 10.3390/molecules27185890] [Reference Citation Analysis]
4 Battista T, Federico S, Brogi S, Pozzetti L, Khan T, Butini S, Ramunno A, Fiorentino E, Orsini S, Di Muccio T, Fiorillo A, Exertier C, Di Risola D, Colotti G, Gemma S, Ilari A, Campiani G. Optimization of Potent and Specific Trypanothione Reductase Inhibitors: A Structure-Based Drug Discovery Approach. ACS Infect Dis 2022. [PMID: 35880849 DOI: 10.1021/acsinfecdis.2c00325] [Reference Citation Analysis]
5 Barazorda-ccahuana HL, Goyzueta-mamani LD, Candia-puma MA, Freitas CSD, Vieria Tavares GDS, Lage DP, Ferraz Coelho EA, Chávez-fumagalli MA. In silico-based screening for natural product’s structural analogs as new drugs candidate against leishmaniasis.. [DOI: 10.1101/2022.07.22.501189] [Reference Citation Analysis]
6 Loiseau PM, Balaraman K, Barratt G, Pomel S, Durand R, Frézard F, Figadère B. The Potential of 2-Substituted Quinolines as Antileishmanial Drug Candidates. Molecules 2022;27:2313. [DOI: 10.3390/molecules27072313] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Silva RC, Santos CBR, Taft CA, Silva GM, de Paula da Silva CHT. Advances in Computational Techniques for Discovery and Development of Drugs Against Leishmaniasis, a Brief Review. Research Topics in Bioactivity, Environment and Energy 2022. [DOI: 10.1007/978-3-031-07622-0_18] [Reference Citation Analysis]